Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: A retrospective analysis

Effect of High-Dose Intravenous Immunoglobulin Administration on the Levels of Interleukin-6 in Patients with Sepsis

“…As all the patients in our study had been administered IVIG on the first day of admission to the ICU, this early administration of IVIG may have contributed to the lower mortality rates. In addition, the mortality rates in our sample are within the range of those reported (approximately 20-50%) in previous studies from other countries [26][27][28][29][30][31].…”

“…In comparison to that study, our sample had a generally low mortality rate regardless of whether the patients had one or more organ dysfunctions. A retrospective analysis on patients with sepsis conducted by Berlot et al [26] found that a large proportion of survivors had received early IVIG therapy. As all the patients in our study had been administered IVIG on the first day of admission to the ICU, this early administration of IVIG may have contributed to the lower mortality rates.…”

IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens

“…IgG responses against certain pneumococcal serotypes may not be effectively mounted until after age 5, and anti-carbohydrate IgG may not reach mature levels until as late as teenage years. 48,49 Moreover, because IgM appears to have a specialized role in combating bloodstream infections, [50][51][52][53][54][55][56] the early propensity of invasive infections in IRAK-4 and MyD88 deficiencies may also be explained by impairment of T-independent IgM. Along these lines, it is notable that IgG replacement therapy is used to treat patients with IRAK-4 and MyD88 deficiencies.…”

Guía colombiana de práctica clínica para el uso de inmonuglobulinas en el tratamiento de reemplazo e inmunomodulación

“…Esta hipótesis se correlaciona con los resultados de un estudio retrospectivo de 129 pacientes adultos tratados con IgIV enriquecida con IgM-A, que mostró beneficio con la administración dentro de las primeras 23 horas. 262,263 En adultos, el uso de IgIV enriquecida con IgM ha mostrado resultados favorables. 264,265,266 Con la revisión de 7 estudios que reunieron 528 pacientes se encontró una reducción muy significativa en la mortalidad en adultos con sepsis severa o choque séptico tratados con IgIV, comparados con los no tratados o sin intervención: RR, 0.…”